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Abstract
Background: No intervention follow-up study has examined the association between plasma n-6 polyunsaturated
fatty acids (PUFAs) and lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a risk factor for cardiovascular
disease (CVD). We aimed to determine whether the administration of linoleic acid (LA, 18:2n-6) in soy oil affected
Lp-PLA2 activity in healthy adults.
Methods: Self-reported healthy participants (n = 150) were randomly assigned to three groups: a low LA group, in
which 10 mL soy oil was replaced with one apple; a medium LA group, in which the typical food intake was
maintained; and a high LA group, in which 1/3 cup of cooked refined rice was replaced with 9.9 g of soy oil
capsules daily. Plasma fatty acids and Lp-PLA2 activity were measured along with other CVD risk factors.
Results: After 8 weeks of treatment, plasma LA levels decreased in the low LA group and increased in the high
LA group. The high LA group showed greater increases in apolipoprotein B (apoB) and oxidized low-density
lipoprotein (ox-LDL) than those in the low LA group. Plasma LA levels and Lp-PLA2 activities demonstrated
greater increases in the high LA group than those in the medium and low LA groups. Changes in plasma LA
positively and independently correlated with changes in Lp-PLA2 activity, which was negatively correlated with
changes in collagen-epinephrine closure time (CEPI-CT).
Conclusions: An increase in plasma LA following intake of soy oil was independently associated with Lp-PLA2
activity, which was also related to apoB, ox-LDL and CEPI-CT.
Trial registration: ClinicalTrail.gov Identifier: NCT02753907, registered 25 April 2016 (retrospectively registered).
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Background
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a
macrophage-derived enzyme that contributes to oxidative
stress, vascular inflammation, and endothelial activation
[1, 2]. Elevated levels of Lp-PLA2 have been associated
with unfavorable health outcomes, including an increased
risk for myocardial infarction and cardiovascular disease
(CVD)-related deaths in adults [3]. Indeed, our previous
study indicated that elevated Lp-PLA2 activity was associ-
ated with prehypertension [4], which reflects an early in-
creased risk of CVD [5]. Furthermore, several studies on
darapladib, a drug that inhibits Lp-PLA2 activity, showed
its beneficial effect on CVD in accordance with decreases
in Lp-PLA2 activity; Mohler et al. [6] reported that dar-
apladib dose-dependently decreased interleukin (IL)-6
in patients with stable coronary disease; Serruys et al.
[7] indicated that its administration to patients with an-
giographically proven coronary disease inhibited the in-
crease in necrotic core volume (coronary atheroma
volume) compared to that of individuals who were not
given the treatment. However, the role of Lp-PLA2 in
CVD is controversial; Blake et al. [8] showed that Lp-
PLA2 activity did not predict CVD events in women
after adjusting for traditional risk factors; Rosenson and
Stafforini [9] reported that it was unclear whether a
mechanism regarding limit necrotic core expansion by
darapladib is a consequence of Lp-PLA2 activity inhibition.
Moreover, the researchers demonstrated that Lp-PLA2
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activity did not predict future risk in individuals who had
adequately managed cholesterol levels in several interven-
tion studies [9]. Thus, the role of Lp-PLA2 as a risk factor
of CVD is unclear.
Omega-3 polyunsaturated fatty acid (n-3 PUFA) sup-
plementation reduces markers of inflammation and
endothelial dysfunction, which are risk factors of CVD,
including atherosclerosis [10]. However, consumption of
large amounts of omega-6 (n-6) PUFAs had proinflam-
matory, prothrombotic, and proaggregatory effects and
promoted the formation of thrombus and atheromas
[11]. Thus, we hypothesized that there is a link between
intake of n-6 PUFAs and Lp-PLA2 activity for the in-
creased risk of CVD. A number of follow-up interven-
tion trials have been performed to examine Lp-PLA2
activity in the context of n-3 fatty acids. However, no
intervention study has examined the association between
changes in plasma n-6 fatty acids and Lp-PLA2 activity,
which is recognized as an independent risk factor for
CVD [2]. Recently, Steffen et al. [12] reported that n-6
fatty acids were independently associated with Lp-PLA2
in their cross-sectional, multi-ethnic study of athero-
sclerosis. Therefore, the present follow-up intervention
study aimed to determine whether 8 weeks of linoleic
acid (LA, C18:2n-6) representing n-6 PUFA administra-
tion in the form of soy oil would alter Lp-PLA2 activity,
as well as other CVD risk factors, in healthy adults.
Methods
Subjects
Subjects were recruited via a poster advertisement in
Seoul, Korea, between June and September of 2015. Sub-
jects who agreed to participate were screened for their
health status. Blood samples were obtained to evaluate
their clinical and biochemical parameters, and self-
reported history of diagnosis and treatment of any dis-
ease, as well as intake of medication or supplements,
was also examined. After the screening, 150 subjects
aged 30–65 years, who were non-diabetic (fasting blood
glucose < 126 mg/dL) and non-obese [a body mass index
(BMI) between 18.5 kg/m2 and 30 kg/m2], had no his-
tory of any disease, and were not using any medication
or supplements, were finally enrolled in this study. Ex-
clusion criteria included dyslipidemia, diabetes mellitus,
hypertension, liver disease, renal disease, chronic disease
of the gastrointestinal tract, cerebrovascular disease,
pancreatitis, cancer, intake of any medication or supple-
ments, and women who were pregnant or lactating.
Drug or alcohol abuse (alcohol consumption >280 g/
week for men, >140 g/week for women) also excluded
participation in the intervention. Written informed consent
was obtained from all participants, and the Institutional Re-
view Board of Yonsei University approved the study proto-
col, which complied with the Helsinki Declaration.
Study design and intervention
An 8-weeks, randomized, placebo-controlled study was
conducted with 150 healthy adults. The participants
were divided into three groups: a low LA group com-
posed of 50 individuals, in which 10 mL soy oil was re-
placed with one apple; a medium LA group (control
group) composed of 50 individuals, in which the typical
food intake was maintained; and a high LA group com-
posed of 50 individuals, in which 1/3 cup of cooked re-
fined rice was replaced with 9.9 g (9 1.1 g capsules, 3
per meal) of soy oil daily as a supplement (Clinical-
Trials.gov: NCT02753907; http://www.clinicaltrials.gov)
[13]. The soy oil capsules were provided by Misuba
RTech Co., Ltd. (Asan, Korea). The soy oil used in this
study contained 54.2% LA, 21.6% oleic acid, 10.7% palmitic
acid, 8.1% α-linolenic acid, and 4.1 mg of α-tocopherol/
100 g [14, 15]. The subjects kept food diaries 3 days before
the baseline visit and for 3 days during weeks 4 (middle of
intervention) and 8 (end of intervention). Individual ses-
sions lasted 1 h and included supportive counseling and
dietary instructions. Group sessions were held separately
for participants in the low LA and high LA groups. The
participants received the same dietary behavioral curricu-
lum, which included identical information on dietary fiber
intake, education on the food pyramid and portion control.
The daily low LA and high LA replacement items (apple or
capsules) were provided to participants in each group for
the duration of the intervention. Participants were coun-
seled to maintain their baseline levels of physical activity,
which was assessed using validated measures at each visit.
Compliance was assessed via the dietary intake record
along with the amount of unconsumed oil capsules or ap-
ples returned at the middle and final visits.
Daily energy intake and physical activity measurements
Details regarding daily energy intake and physical activity
have been previously published [16]. Briefly, a standardized
3-days dietary record (2 weekdays and 1 weekend day) was
obtained from each participant. This record was completed
at home after the participants received detailed explana-
tions from a dietitian. This measurement was performed
during weeks 0, 4, and 8. A computerized version of the
Korean Nutrition File (Can-Pro 3.0; The Korean Nutrition
Society, Seoul, Korea) was used to determine the macronu-
trient content of the foods consumed by the participants
and their total daily energy intake. In addition, the partici-
pants completed a semi-quantitative food frequency ques-
tionnaire and a 24-h recall with the assistance of a dietitian
on weeks 0, 4, and 8 to confirm the accuracy of the dietary
record. A standardized 3-days physical activity record was
also completed at home on the same days that the dietary
record was completed, and total energy expenditure was
calculated.
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Anthropometric parameters and blood pressure
Detailed information on these parameters is provided in
our previous paper [16]. Briefly, body weight, height and
waist circumference were measured at screening, baseline
and the 8-weeks follow-up visit. BMI was calculated in
units of kilograms per square meter (kg/m2). During each
testing session, systolic and diastolic blood pressure values
were measured in a supine position after a resting period.
Biochemical analyses and plasma Lp-PLA2 activity and
oxidized LDL
Detailed information has been previously published [16].
Briefly, blood samples were collected following an overnight
fast of at least 12 h, and the levels of fasting triglycerides;
total-, high-density lipoprotein (HDL)-, and low-density
lipoprotein (LDL)-cholesterol; apolipoprotein (apo) A-I and
B; glucose; insulin; and high-sensitivity C-reactive protein
(hs-CRP) were measured. The activity of Lp-PLA2, also
known as platelet-activating factor acetylhydrolase (PAF-
AH), was measured using a PAF-AH activity assay kit
(Biovision, Milpitas, CA). The resulting change in absorb-
ance was immediately read at 412 nm for 30 min at room
temperature using a VERSAmax microplate reader in kin-
etic mode (Molecular Devices, Sunnyvale, CA). Lp-PLA2
activity was expressed in nmol of PAF hydrolyzed per min
per mL of serum. Plasma oxidized LDL (ox-LDL) was
measured using an enzyme immunoassay (Mercodia AB,
Uppsala, Sweden). The resulting color reaction was moni-
tored at 450 nm with a Wallac 1420 Victor2 multilabel
counter (PerkinElmer Life Sciences, Boston, MA).
Hemostasis tests
The details of the hemostasis tests have been previously
published [16]. Blood samples used for the platelet function
analyzer-100 (PFA-100; Siemens, Marburg, Germany) assay
were collected in 2.7 mL tubes containing 3.2% sodium
citrate and analyzed independently. Collagen-epinephrine
closure time (CEPI-CT) was analyzed using a PFA-100
system according to the manufacturer’s instructions. Pro-
thrombin time (PT) and activated partial thromboplastin
time (aPTT) were measured using a Sysmex CA-1500 co-
agulation analyzer (Sysmex, Nagano, Japan). The fibrino-
gen concentration was determined via a light scattering
method with the Sysmex CA-1500 coagulation analyzer.
Fatty acid concentrations using gas chromatography
mass spectrometry (GC-MS)
The details of GC-MS have been previously published
[16]. Briefly, all analyses were performed on an Agilent
Technologies 7890 N gas chromatograph coupled to an
Agilent Technologies 5977A quadrupole mass selective
spectrometer with a triple-axis detector (Agilent, Palo
Alto, CA) in the electron ionization mode (70 eV) and
full scan monitoring mode (m/z 50–800). Derivatized
samples were separated on a VF-WAX column (Agilent
Technologies, Middelburg, Netherlands) with helium as
the carrier gas and a temperature ramp from 50 °C to
230 °C. Metabolites in the samples were identified by
comparing their relative retention times and mass
spectra with those of authentic reference standards.
The relative metabolite levels were calculated by com-
paring their peak areas to that of the internal standard
compound.
Statistical analysis
Statistical analysis was performed using SPSS version 21.0
(IBM/SPSS, Chicago, IL). Logarithmic transformation was
performed on skewed variables. For descriptive purposes,
the mean values are presented using untransformed values.
The results are expressed as the mean ± standard error. A
two-tailed P-value <0.05 was considered statistically
significant. We compared the parameters at baseline
and at the 8-weeks follow-up visit, and the net change
(difference from baseline) among the low, medium, and
high LA groups was assessed using one-way analysis of
variance (ANOVA) with a Bonferroni post hoc test. Paired
t-tests were performed to compare the effects of the inter-
vention within each group. A stepwise multiple regression
analysis was performed to identify the major variables in-
fluencing Lp-PLA2 activity. Pearson’s correlation coeffi-
cient was used to examine relationships between variables.
A heat map was generated to visualize correlations among
variables.
Results
Among the enrolled subjects (n = 150), 3 dropped out
for personal reasons, and 147 subjects completed the
study. Among the dropouts, all 3 were in the control
(medium LA) group and maintained their usual dietary
intake. Thus, the compliance rate based on returned
capsules and apples was high (98.5%), and no adverse re-
actions involving supplementation with soy oil were ob-
served. The soy oil used in this study contained 54.2% LA,
21.6% oleic acid 10.7% palmitic acid, 8.1% α-linolenic acid
and 4.1 mg of α-tocopherol/100 g [14, 15]. There were no
reports of adverse events from study participants in all
three groups during the study period.
Clinical characteristics
No significant differences in the baseline measurements
between the 3 dietary groups were found for age, BMI,
daily energy intake, % carbohydrate, % protein, and % fat
of total energy, blood pressure, lipid profiles, glucose,
insulin, hemostatic markers and plasma levels of the four
n-6 and three n-3 PUFAs (Table 1 and Fig. 1). After the
intervention period, carbohydrates substantially increased
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in the low LA group as they were given an apple instead of
LA supplements, whereas they significantly decreased in
the high LA group, who consumed extra LA instead of 1/3
cup of cooked refined rice. The means of the dietary fat in-
take were broadly met, with changes of −2.3, −0.1, and
3.4% in the respective diets (low LA group, medium LA
group and high LA group) relative to the baseline intake.
During the intervention, the ratio of PUFAs to saturated
fatty acids significantly increased from 1.20 to 1.75 in the
high LA group; thus, all dietary characteristics showed the
expected changes. There were no significant differences in
physical activity levels among the three groups at baseline,
4, and 8 weeks.
Plasma fatty acid levels
Relative levels of the following plasma values of PUFAs
are shown in Fig. 1 and Table 1: LA (18:2n-6); gamma-
linolenic acid (GLA, 18:3n-6); dihomo-gamma-linolenic
acid (DGLA, 20:3n-6); arachidonic acid (AA, 20:4n-6);
alpha-linolenic acid (ALA, 18:3n-3); eicosapentaenoic
acid (EPA, 20:5n-3); and docosahexaenoic acid (DHA,
22:6n-3). Significant effects on overall dietary fat due to
changes (difference from baseline) in LA intake between
the groups were broadly supported by changes in the
plasma LA levels, which were significantly different be-
tween groups (P < 0.001) (Fig. 1). Plasma LA levels de-
creased by 12.2% in the low LA group and increased by
13.8% in the high LA group after diet intervention from
the baseline values (Fig. 1). The low LA group showed a
significant decrease from baseline in plasma LA, GLA
and DGLA, whereas the high LA group showed in-
creases in plasma LA, GLA, DGLA and AA, and these
changes in plasma LA (P < 0.001), GLA (P = 0.001), ALA
(P = 0.018), DGLA (P < 0.001) and AA (P = 0.015) were
significantly different between the groups (Fig. 1 and
Table 1). At week 8, plasma LA (Fig. 1), ALA (P = 0.004)
and DGLA (P = 0.008) were higher in the high LA group
than that in the low LA group (Table 1).
Blood pressure, glucose, and serum lipid profiles
The low LA group showed significant decreases from
baseline in diastolic blood pressure, total cholesterol and
LDL-cholesterol at 8 weeks (Table 1). Changes in total
cholesterol (P < 0.001) and LDL-cholesterol (P = 0.003)
were significantly different between groups, and greater
reductions in the low LA group were observed than those
in the high LA group. The high LA group also showed sig-
nificant increases in serum apoB and plasma ox-LDL at
8 weeks. The changes in the serum apoB (P = 0.010) and
plasma ox-LDL (P = 0.018) were significantly different
between groups, with increases observed in the high LA
group and decreases in the low LA group.
hs-CRP, hemostatic markers and Lp-PLA2 activity
The low LA group showed significant increases from
baseline in hs-CRP, fibrinogen and aPTT at 8 weeks
(Table 1). The high LA group showed significant increases
from baseline in plasma Lp-PLA2 activity at 8 weeks. The
changes in the plasma Lp-PLA2 activity were significantly
different between groups (P = 0.002), with increases
observed in the high LA group and decreases in both the
medium LA and low LA groups (Fig. 1).
Correlations among changes in the plasma fatty acid
levels, LDL, ox-LDL, apoB, CRP, hemostatic markers and
Lp-PLA2 activity
Figure 2 shows the correlations among changes in plasma
fatty acid levels, LDL, ox-LDL, apoB, CRP, hemostatic
markers and Lp-PLA2 activity in all participants (n = 147).
The changes in plasma LA were positively correlated with
the changes in GLA, ALA, DGLA, AA, Lp-PLA2 activity
(all P-values < 0.001), apoB (P = 0.002), ox-LDL (P = 0.001)
and LDL-cholesterol (P = 0.001). The changes in Lp-PLA2
activity were positively correlated with the changes in LA
(Fig. 3, r = 0.322, P < 0.001), DGLA (P = 0.002), AA (P =
0.038), LDL-cholesterol (P < 0.001), ox-LDL (P < 0.001)
and apoB (P < 0.001) but were negatively correlated with
the changes in CEPI-CT (Fig. 3, r = -0.266, P = 0.001) and
also showed a trend toward a negative correlation with
aPTT (P = 0.062). Other correlations among plasma fatty
acid levels, LDL, ox-LDL, apoB, CRP, hemostatic markers
and Lp-PLA2 activity are shown in Fig. 2 (P-values are
available in Additional file 1).
Because the regulation of Lp-PLA2 activity is complex,
a multiple linear regression analysis was performed to
determine the independent effects of the following vari-
ables on Lp-PLA2 activity: age, BMI, gender, baseline
Lp-PLA2 and changes in LDL-cholesterol, ox-LDL, LA,
apoB, GLA, DGLA, AA, ALA, EPA, and DHA. Lp-PLA2
activity was affected by baseline Lp-PLA2 activity (β = –
0.228; CI: –2.432, –0.511), as well as changes in apoB
(β = 0.304; CI: 0.019, 0.058) and plasma LA (β = 0.198;
CI: 0.187, 1.358) (R2 = 0.255, P = 0.010).
Discussion
This study examined whether changes in LA intake in
the form of soy oil over 8 weeks would alter Lp-PLA2
activity, which is an independent risk factor for CVD.
The results showed that 8 weeks of daily 10 mL supple-
mentation with soy oil, equivalent to approximately
5 mL of LA, increased the plasma LA levels by 14% and
Lp-PLA2 activity by 6.2% without changes in LDL-
cholesterol levels. Thus, the major finding of the present
study is that when the total energy intake was kept con-
stant, an increase in plasma LA from intake of soy oil
was independently associated with an increase in Lp-
PLA2 activity in non-diabetic and non-obese healthy
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Table 1 Clinical and biochemical characteristics and plasma levels of fatty acids of each groups according to linoleic acid intake
Low LA (n = 50) Medium LA (n = 47) High LA (n = 50) Pa Pb Pc
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Age (year) 52.7 ± 0.99 52.0 ± 1.13 52.7 ± 1.13 0.861
Male/Female n, (%) 9 (18.0)/41 (82.0) 5 (10.6)/42 (89.4) 9 (18.0)/41 (82.0) 0.519
BMI (kg/m2) 23.9 ± 0.41 23.8 ± 0.41 24.4 ± 0.46 24.4 ± 0.46 24.5 ± 0.43 24.5 ± 0.43 0.530 0.481
Estimated energy intake
(kcal/d)†
2093.3 ± 30.2 2103.4 ± 24.7 2106.0 ± 23.0 2095.9 ± 24.6 2094.8 ± 24.0 2097.4 ± 30.8 0.993 0.978
Carbohydrate (% of energy)† 61.7 ± 0.11 64.5 ± 0.32a,*** 61.4 ± 0.16 61.2 ± 0.23b 61.8 ± 0.10 58.1 ± 0.40c,*** 0.080 <0.001
Protein (% of energy)† 16.5 ± 0.10 16.2 ± 0.45 16.4 ± 0.15 16.8 ± 0.18 16.5 ± 0.12 16.7 ± 0.14 0.858 0.381
Fat (% of energy)† 21.9 ± 0.11 19.6 ± 0.38c,*** 22.1 ± 0.07 22.0 ± 0.09b 22.0 ± 0.10 25.4 ± 0.40a,*** 0.373 <0.001
PUFA/SFA† 1.24 ± 0.02 1.30 ± 0.04b 1.23 ± 0.01 1.22 ± 0.01b 1.20 ± 0.01 1.75 ± 0.01a,*** 0.389 <0.001
n-6/n-3† 9.79 ± 0.28 9.25 ± 0.36b 9.75 ± 0.37 9.66 ± 0.34a,b 9.83 ± 0.26 10.7 ± 0.26a,* 0.928 0.003
γ-linolenic acid (C18:3, n-6)‡ 0.194 ± 0.017 0.162 ± 0.011* 0.185 ± 0.011 0.182 ± 0.010 0.176 ± 0.016 0.208 ± 0.020* 0.692 0.070
Change −0.032 ± 0.014b −0.003 ± 0.007a,b 0.032 ± 0.015a 0.001
α-linolenic acid (C18:3, n-3)‡ 0.139 ± 0.018 0.120 ± 0.011b 0.125 ± 0.010 0.129 ± 0.011b 0.159 ± 0.017 0.188 ± 0.021a 0.319 0.004
Change −0.020 ± 0.013b 0.004 ± 0.004a,b 0.029 ± 0.015a 0.018
Dihomo-γ-linolenic acid
(C20:3, n-6)‡
0.146 ± 0.005 0.130 ± 0.007b,** 0.154 ± 0.005 0.155 ± 0.005a 0.142 ± 0.007 0.157 ± 0.008a,* 0.345 0.008
Change −0.016 ± 0.005b 0.001 ± 0.005a,b 0.014 ± 0.005a <0.001
Arachidonic acid (C20:4, n-6)‡ 0.647 ± 0.016 0.632 ± 0.017 0.666 ± 0.019 0.670 ± 0.019 0.654 ± 0.020 0.691 ± 0.019** 0.753 0.062
Change −0.015 ± 0.015b 0.004 ± 0.011a,b 0.038 ± 0.013a 0.015
Eicosapentaenoic acid
(C20:5, n-3)‡
0.233 ± 0.016 0.236 ± 0.015 0.230 ± 0.018 0.239 ± 0.016 0.211 ± 0.017 0.197 ± 0.011 0.604 0.071
Docosahexaenoic acid
(C22:6, n-3)‡
0.428 ± 0.025 0.411 ± 0.023 0.446 ± 0.030 0.440 ± 0.028 0.458 ± 0.024 0.455 ± 0.019 0.715 0.404
Systolic BP (mmHg) 123.1 ± 1.82 120.5 ± 1.76 120.2 ± 1.92 117.8 ± 1.76 122.1 ± 1.78 123.1 ± 1.77 0.543 0.106
Diastolic BP (mmHg) 79.5 ± 1.42 76.9 ± 1.24* 76.8 ± 1.34 74.5 ± 1.23* 77.4 ± 1.22 77.3 ± 1.26 0.333 0.243
Prothrombin time (sec) 10.5 ± 0.07 10.6 ± 0.08 10.7 ± 0.08 10.7 ± 0.08 10.6 ± 0.08 10.6 ± 0.07 0.552 0.730
Activated partial thromboplastin
time (sec)
26.3 ± 0.37 26.9 ± 0.42* 27.3 ± 0.35 27.4 ± 0.40 26.4 ± 0.33 26.5 ± 0.35 0.103 0.288
Fibrinogen (mg/dL) 260.7 ± 5.12 272.1 ± 6.54* 269.0 ± 6.51 270.9 ± 6.33 267.4 ± 5.27 263.0 ± 4.63 0.541 0.491
CEPI-CT (sec) 142.4 ± 7.37 144.4 ± 8.20 141.2 ± 5.50 141.4 ± 7.88 151.3 ± 8.41 144.2 ± 7.26 0.561 0.694
Triglyceride (mg/dL)∮ 132.3 ± 10.2 117.4 ± 8.38 123.1 ± 8.57 122.1 ± 9.71 136.8 ± 12.7 169.6 ± 28.3 0.938 0.137
Total-cholesterol (mg/dL)∮ 228.3 ± 3.44 210.1 ± 4.40b,*** 231.2 ± 3.91 227.5 ± 3.90a 222.0 ± 3.94 227.4 ± 6.09a 0.182 0.018
Change −18.1 ± 3.71b −3.68 ± 3.70a 5.42 ± 4.52a <0.001
HDL-cholesterol (mg/dL)∮ 55.4 ± 2.09 55.8 ± 2.02 58.6 ± 2.55 60.3 ± 2.64 51.1 ± 2.03 53.9 ± 2.60 0.081 0.136
LDL-cholesterol (mg/dL)∮ 146.5 ± 3.54 129.1 ± 3.50b,*** 148.0 ± 3.63 142.8 ± 3.55a 143.7 ± 3.74 143.3 ± 4.61a 0.670 0.017
Change −17.4 ± 3.49a −5.14 ± 3.69a,b −0.14 ± 3.77b 0.003
Apolipoprotein A-I (mg/dL)∮ 162.8 ± 4.14 161.2 ± 3.50 167.9 ± 5.07 170.5 ± 4.65 152.7 ± 3.59 156.6 ± 4.15 0.065 0.059
Apolipoprotein B (mg/dL)∮ 126.4 ± 3.85 122.3 ± 3.69 128.7 ± 3.48 127.9 ± 3.29 121.2 ± 3.48 127.6 ± 3.29* 0.305 0.349
Change −4.06 ± 2.56b −0.85 ± 2.34a,b 6.44 ± 2.54a 0.010
Glucose (mg/dL)∮ 89.5 ± 1.35 89.3 ± 1.36 88.1 ± 1.11 87.9 ± 1.15 87.6 ± 0.97 86.3 ± 1.23 0.564 0.250
Insulin (μIU/mL)∮ 8.56 ± 0.51 8.41 ± 0.43 8.95 ± 0.50 8.81 ± 0.52 8.63 ± 0.57 8.70 ± 0.64 0.615 0.895
hs-CRP (mg/L)∮ 0.53 ± 0.06 0.83 ± 0.16* 0.79 ± 0.16 0.75 ± 0.11 0.77 ± 0.13 0.73 ± 0.13 0.253 0.641
Oxidized LDL (U/L)∮ 63.6 ± 1.98 61.9 ± 1.91 61.6 ± 2.29 61.9 ± 2.66 63.6 ± 2.68 67.9 ± 2.32** 0.714 0.084
Change −1.74 ± 1.38b 0.30 ± 1.55a,b 4.27 ± 1.61a 0.018
Mean ± SE. †Values were estimated from weighed food records and calculated using the database of the computerized Korean food code. ‡All units of GC-MS
data are relative peak area. ∮Values were tested by logarithmic transformation. Pa-values derived from ANOVA in baseline. Pb-values derived from ANOVA in follow
up. Pc-values derived from ANOVA in changed value. All alphabetical P < 0.05 derived from the Bonferroni post hoc test in baseline, follow-up, and changed value,
respectively; no significant changes among the each group marked with the same letters and significant changes among the each group marked in different
letters. *P <0.05, **P <0.01, ***P <0.001 indicate comparisons with baseline values in each group performed with a paired t-test
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Fig. 1 Plasma levels of LA and Lp-PLA2 activity at baseline (□) and 8 weeks of follow-up (■) according to LA intake. Mean ± SE. Data included 50
(low LA), 47 (medium LA) and 50 (high LA) participants. §Values were tested by logarithmic transformation. P-values were derived from ANOVA.
All alphabetical P < 0.05 values were derived from ANOVA with the Bonferroni post hoc test in follow-up and changed values; no significant
changes among each group are indicated with the same letter, while significant changes among each group are indicated with a different letter.
*P < 0.05, **P < 0.01, ***P < 0.001 indicate comparisons with baseline values in each group performed with a paired t-test
Fig. 2 Correlation matrix among changes in plasma fatty acid levels, LDL, ox-LDL, apoB, hs-CRP, hemostatic markers and Lp-PLA2 activity. Correlations
were obtained using Pearson’s correlation coefficient. Red indicates a positive correlation, and blue indicates a negative correlation
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subjects who were not taking any medications or supple-
ments that could affect lipid metabolism, platelet func-
tion or inflammation.
To date, no dietary intervention studies have examined
changes in n-6 fatty acids in the context of Lp-PLA2
activity, and only one cross-sectional study with a large
population examined the potential association between
Lp-PLA2 activity and plasma fatty acid levels [12].
Steffen et al. showed that Lp-PLA2 mass and activity
were significantly higher in participants with greater
plasma levels of LA and DGLA [12]. In this study, the
change (difference from baseline) in Lp-PLA2 activity
was associated with changes in plasma n-6 PUFAs,
including LA, DGLA and AA; however, a multiple
regression analysis revealed that only the change in LA
was independently and positively correlated with the
change in Lp-PLA2 activity—a hallmark of inflammation,
atherosclerosis and CVD [2, 12].
As a major unsaturated fatty acid in the diet, LA is
considered to be atherogenic because of its pro-oxidative
and proinflammatory properties [12, 17, 18]. Thus, the
positive association between changes in plasma LA and
Lp-PLA2 activity in this study may be explained by the
influence of LA on inflammation. Hennig et al. [17] also
reported that the positive association between LA and Lp-
PLA2 was due to its promotion of inflammation and the
activation of phosphoinositol 3-kinase in cell culture
models [17]. Indeed, there is a considerable body of evi-
dence showing that LA affects inflammatory signaling
cascades, which may in turn influence Lp-PLA2
expression via phosphatidylinositol 3-kinase and p38
mitogen-activated protein kinase. However, further re-
search is needed to determine whether these effects are
involved in the induction of Lp-PLA2 expression in vivo.
Additionally, an increase in Lp-PLA2 activity was also
related to increases in apoB and ox-LDL and a decrease
in CEPI-CT. Ox-LDL is generated under oxidative stress
[19], which is caused by increased LA and Lp-PLA2
activity [1, 2, 12, 17, 18]. LA was positively correlated
with Lp-PLA2 activity in the present study, suggesting
that oxidative stress is enhanced in the high LA group.
Moreover, Wang et al. [20] demonstrated that ox-LDL
stimulated expression of Lp-PLA2; therefore, a vicious
cycle of ox-LDL generation by elevated LA or Lp-PLA2-
induced oxidative stress and increased Lp-PLA2 due to
ox-LDL might occur in the body. CEPI-CT has previ-
ously been related to bleeding time [21] and shown to
serve as a method to identify high residual platelet re-
activity despite aspirin therapy, thereby predicting the
risk of ischemic events [22]. Thus, a negative correlation
between changes in Lp-PLA2 activity and CEPI-CT and
a positive correlation between changes in the plasma LA
level and Lp-PLA2 activity could suggest an increase in
the plasma LA level from increased dietary LA intake.
Additionally, aPTT, as a functional assay, is accurate and
highly reproducible and can identify abnormalities within
the coagulation pathway [22]. In this study, the low LA
group showed significantly increased aPTT (by 3.5%) at
8 weeks and a trend toward a negative correlation between
changes in Lp-PLA2 activity and aPTT.
Fig. 3 Correlations among changes in Lp-PLA2 activity, LA, and CEPI-CT. r: Pearson’s correlation coefficients
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There was an increase in fibrinogen and hs-CRP
within the normal range in the low LA group, despite
significant reductions in LDL- and total-cholesterol.
These findings may indicate a transient phenomenon
present during the transition from normal LA intake to
low LA intake. Similarly, Tylner et al. [23] observed a
negative relationship between changes in fibrinogen and
the intake of an energy-dense formula with oleic and LA
in older, frail adults with a lower dietary intake than
their estimated needs.
The present study has several strengths, including
dietary intervention with different levels of LA and the
direct measurement of plasma fatty acid levels compared
with that of previous studies, as well as indirect mea-
surements of fat intake from dietary recall. Additionally,
numerous demographic, lifestyle and clinical factor ad-
justments were made to better determine whether
changes in LA were associated with changes in Lp-PLA2
activity. In terms of limitations, the fat intake in the
medium LA dietary group (control group) is typical for
the Korean population but much lower than that in
Western countries. Thus, the results of this study cannot
be generalized to other populations with a higher fat in-
take. Furthermore, it should be noted that the role in
Lp-PLA2 is still controversial. Despite these limitations,
the present findings indicate that higher plasma LA
levels, resulting from a higher dietary LA intake, are as-
sociated with higher Lp-PLA2 activity, as well as in-
creases in apoB and ox-LDL and decreases in CEPI-CT.
Conclusions
An increase in plasma LA following oral intake of soy oil
for 8 weeks elevated apoB, ox-LDL, and Lp-PLA2 activity
in healthy subjects. Changes in plasma LA positively and
independently correlated with changes in Lp-PLA2 activity,
which was negatively correlated with changes in CEPI-CT.
Our results suggest that consumption of n-6 fatty acids, es-
pecially LA, is associated with increases in Lp-PLA2 activity
and CEPI-CT, and these increases may be mediated by
elevated oxidative stress.
Additional file
Additional file 1: P-values for correlations among changes in (Δ) plasma
fatty acid level, LDL-cholesterol, oxidized LDL, apolipoprotein B, hs-CRP,
hemostatic markers and Lp-PLA2 activity. P-values were derived from
Pearson’s correlation coefficients. (DOCX 29 kb)
Abbreviations
ALA: Alpha-linolenic acid; ANOVA: One-way analysis of variance;
apo: Apolipoprotein; aPTT: Activated partial thromboplastin time;
CEPI-CT: Collagen-epinephrine closure time; CVD: Cardiovascular disease;
DGLA: Dihomo-gamma-linolenic acid; DHA: Docosahexaenoic acid;
EPA: Eicosapentaenoic acid; GC-MS: Gas chromatography mass spectrometry;
GLA: Gamma-linolenic acid; HDL: High-density lipoprotein; hs-CRP:
High-sensitivity C-reactive protein; LA: Linoleic acid; LDL: Low-density
lipoprotein; Lp-PLA2: Lipoprotein-associated phospholipase A2; ox-LDL: Oxidized





This work was supported by the Bio-Synergy Research Project of the Ministry
of Science, ICT and the Future Planning through the National Research
Foundation, Republic of Korea [NRF-2012M3A9C4048762]; the Korean Health
Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
[HI14C2686010115 and HI14C2686].
Availability of data and materials
The datasets generated during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
MKK contributed to analysis and interpretation of the data and drafted the
manuscript. MJK contributed to analysis and interpretation of the data and
drafted the manuscript. AL contributed to acquisition and analysis of the
data. HJY contributed to analysis and interpretation of the data and drafted
the manuscript. JSH contributed to acquisition and analysis of the data. SHJ
contributed to conception and design of the research and acquisition and
interpretation of the data. JHL contributed to conception and design of the
research, contributed to analysis and interpretation of the data, and drafted
the manuscript. All authors critically revised the manuscript, read and
approved the final manuscript, and agree to be fully accountable for
ensuring the integrity and accuracy of the work.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Written informed consent was obtained from all participants, and the
Institutional Review Board of Yonsei University approved the study protocol,
which complied with the Helsinki Declaration.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei
University, Seoul 03722, Korea. 2National Leading Research Laboratory of
Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition,
College of Human Ecology, Yonsei University, Seoul 03722, Korea.
3Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of
Human Ecology, Yonsei University, Seoul 03722, Korea. 4Institute for Health
Promotion, Graduate School of Public Health, Yonsei University, Seoul 03722,
Korea.
Received: 10 August 2016 Accepted: 28 April 2017
References
1. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al.
Lipoprotein-associated phospholipase A2, platelet-activating factor
acetylhydrolase, generates two bioactive products during the oxidation of
low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–87.
2. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation
and cardiovascular risk prediction. Vasc Health Risk Manag. 2006;2:153–6.
3. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, et al.
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of
cardiovascular disease in older adults: results from the cardiovascular health
study. Atherosclerosis. 2010;209:528–32.
Kim et al. Nutrition & Metabolism  (2017) 14:32 Page 8 of 9
4. Kim M, Jung S, Kim SY, Lee SH, Lee JH. Prehypertension-associated elevation
in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative
stress. PLoS One. 2014;9:e96735.
5. Cha TW, Kim M, Kim M, Chae JS, Lee JH. Blood pressure-lowering effect of
Korean red ginseng associated with decreased circulating Lp-PLA2 activity
and lysophosphatidylcholines and increased dihydrobiopterin level in
prehypertensive subjects. Hypertens Res. 2016;39:449–56.
6. Mohler 3rd ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM,
Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated
phospholipase A2 activity and cardiovascular biomarkers in patients with
stable coronary heart disease or coronary heart disease risk equivalent: the
results of a multicenter, randomized, double-blind, placebo-controlled
study. J Am Coll Cardiol. 2008;51:1632–41.
7. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann
M, et al. Effects of the direct lipoprotein-associated phospholipase A(2)
inhibitor darapladib on human coronary atherosclerotic plaque. Circulation.
2008;118:1172–82.
8. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of
lipoprotein-associated phospholipase A(2) levels and the risk of future
cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–6.
9. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation,
and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res.
2012;53:1767–82.
10. Kromhout D, de Goede J. Update on cardiometabolic health effects of ω-3
fatty acids. Curr Opin Lipidol. 2014;25:85–90.
11. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio
increases the risk for obesity. Nutrients. 2016;8:128.
12. Steffen BT, Steffen LM, Liang S, Tracy R, Jenny NS, Tsai MY. n-3 and n-6 fatty
acids are independently associated with lipoprotein-associated
phospholipase A 2 in the multi-ethnic study of atherosclerosis. Br J Nutr.
2013;110:1664–71.
13. ClinicalTrials.gov. Impact of an 8-weeks linoleic acid intake in soy oil on Lp-
PLA2 activity in healthy adults. 2016. https://clinicaltrials.gov/ct2/show/
NCT02753907. Accessed 25 Apr 2016.
14. Rural Development Administration. Food composition table. 7th ed. Suwon,
South Korea: Rural Development Administration; 2006.
15. Rural Development Administration. Fat-soluble vitamin composition table.
Suwon, South Korea: Rural Development Administration; 2012.
16. Kim M, Kim M, Lee YJ, Lee SP, Kim TS, Yang HJ, et al. Effects of α-linolenic
acid supplementation in perilla oil on collagen-epinephrine closure time,
activated partial thromboplastin time and Lp-PLA2 activity in non-diabetic
and hypercholesterolaemic subjects. J Funct Foods. 2016;23:95–104.
17. Hennig B, Lei W, Arzuaga X, Ghosh DD, Saraswathi V, Toborek M. Linoleic acid
induces proinflammatory events in vascular endothelial cells via activation of
PI3K/Akt and ERK1/2 signaling. J Nutr Biochem. 2006;17:766–72.
18. Hennig B, Toborek M, McClain CJ. High-energy diets, fatty acids and
endothelial cell function: implications for atherosclerosis. J Am Coll Nutr.
2001;20:97–105.
19. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated
phospholipase A2 (Lp-PLA2): a review of its role and significance as a
cardiovascular biomarker. Biomarkers. 2012;17:289–302.
20. Wang WY, Li J, Yang D, Xu W, Zha RP, Wang YP. OxLDL stimulates
lipoprotein-associated phospholipase A2 Expression in THP-1 monocytes via
PI3K and p38 MAPK pathways. Cardiovasc Res. 2010;85:845–52.
21. Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of
PFA-100® testing in the diagnostic screening of patients with suspected
abnormalities of hemostasis: comparison with the bleeding time. J Thromb
Haemost. 2007;5:2393–8.
22. Reny J-L, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100™ closure
time to predict cardiovascular events in aspirin-treated cardiovascular patients:
a systematic review and meta-analysis. J Thromb Haemost. 2008;6:444–50.
23. Tylner S, Cederholm T, Faxén-Irving G. Effects on weight, blood lipids, serum
fatty acid profile and coagulation by an energy-dense formula to older care
residents: a randomized controlled crossover trial. J Am Med Dir Assoc.
2016;17:275.e5–11.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. Nutrition & Metabolism  (2017) 14:32 Page 9 of 9
